Functional proteomics to dissect tyrosine kinase signalling pathways in cancer

Nature Reviews Cancer

Volumn 10, Issue 9, 2010, Pages 618-629

  Kolch, Walter ^a   Pitt, Andrew ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BREAKPOINT CLUSTER REGION PROTEIN; CAMPTOTHECIN; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; VORINOSTAT;

BREAST CANCER; CANCER RESEARCH; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UBIQUITINATION;

ANIMALS; HUMANS; NEOPLASMS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-TYROSINE KINASES; PROTEOMICS; SIGNAL TRANSDUCTION;

EID: 77955942384     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2900     Document Type: Review

References (153)

1. Wolf-Yadlin, A., Sevecka, M. & MacBeath, G. Dissecting protein function and signaling using protein microarrays. Curr. Opin. Chem. Biol. 13, 398-405 (2009).
2. Schulz, K. R., Danna, E. A., Krutzik, P. O. & Nolan, G. P. Single-cell phospho-protein analysis by flow cytometry. Curr. Protoc. Immunol. 78, 8.17.1-8.17.20 (2007).
3. Fournier, F. et al. Biological and biomedical applications of two-dimensional vibrational spectroscopy: proteomics, imaging, and structural analysis. Acc. Chem. Res. 42, 1322-11231 (2009).
4. Faley, S. L. et al. Microfluidic single cell arrays to interrogate signalling dynamics of individual, patient-derived hematopoietic stem cells. Lab Chip 9, 2659-2664 (2009).
5. Melo, J. V. & Barnes, D. J. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Rev. Cancer 7, 441-453 (2007).
6. Burckstummer, T. et al. An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nature Methods 3, 1013-1019 (2006).
7. Gavin, A. C. et al. Proteome survey reveals modularity of the yeast cell machinery. Nature 440, 631-636 (2006).
8. Krogan, N. J. et al. Global landscape of protein complexes in the yeast Saccharomyces cerevisiae. Nature 440, 637-643 (2006).
9. Bublil, E. M. & Yarden, Y. The EGF receptor family: spearheading a merger of signaling and therapeutics. Curr. Opin. Cell Biol. 19, 124-134 (2007).
10. Hammond, D. E. et al. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J. Proteome Res. 9, 2734-2742 (2010).
11. Gordus, A. et al. Linear combinations of docking affinities explain quantitative differences in RTK signaling. Mol. Syst. Biol. 5, 235 (2009).
12. Mitsudomi, T. & Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277, 301-308 (2010).
13. Dengjel, J., Kratchmarova, I. & Blagoev, B. Receptor tyrosine kinase signaling: a view from quantitative proteomics. Mol. Biosyst. 5, 1112-1121 (2009).
14. von Kriegsheim, A., Preisinger, C. & Kolch, W. Mapping of signaling pathways by functional interaction proteomics. Methods Mol. Biol. 484, 177-192 (2008).
15. Preisinger, C., von Kriegsheim, A., Matallanas, D. & Kolch, W. Proteomics and phosphoproteomics for the mapping of cellular signalling networks. Proteomics 8, 4402-4415 (2008).
16. Ong, S.-E. & Mann, M. Mass spectrometry-based proteomics turns quantitative. Nature Chem. Biol. 1, 252-262 (2005).
17. Blagoev, B. & Mann, M. Quantitative proteomics to study mitogen-activated protein kinases. Methods 40, 243-250 (2006).
18. Cheng, X. Understanding signal transduction through functional proteomics. Expert Rev. Proteomics 2, 103-116 (2005).
19. Andersen, J. S. et al. Proteomic characterization of the human centrosome by protein correlation profiling. Nature 426, 570-574 (2003).
20. Amit, I., Wides, R. & Yarden, Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol. 3, 151 (2007).
21. Papanikolaou, N. A. & Papavassiliou, A. G. Protein complex, gene, and regulatory modules in cancer heterogeneity. Mol. Med. 14, 543-545 (2008).
22. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
23. Henson, E. S. & Gibson, S. B. in Signal Transduction: Pathways, Mechanisms and Diseases (ed. Sitaramayya, A.) 119-141 (Springer-Verlag, New York, 2010).
24. Blagoev, B., Kratchmarova, I., Olsen, J. V. & Mann, M. in EGFR Signaling Networks in Cancer Therapy (eds Haley, J. D. & Gullick, W. J.) 190-198 (Springer-Verlag, New York, 2008).
25. Kholodenko, B. N. Cell-signalling dynamics in time and space. Nature Rev. Mol. Cell Biol. 7, 165-176 (2006).
26. Wiley, H. S., Shvartsman, S. Y. & Lauffenburger, D. A. Computational modeling of the EGF-receptor system: a paradigm for systems biology. Trends Cell Biol. 13, 43-50 (2003).
27. Schulze, W. X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 2005.0008 (2005).
28. Jones, R. B., Gordus, A., Krall, J. A. & MacBeath, G. A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature 439, 168-174 (2006).
29. Alroy, I. & Yarden, Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410, 83-86 (1997).
30. Normanno, N. et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366, 2-16 (2006).
31. Von Kriegsheim, A. et al. Cell fate decisions are specified by the dynamic ERK interactome. Nature Cell Biol. 11, 1458-U172 (2009).
32. Yoon, S. & Seger, R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 24, 21-44 (2006).
33. Irvine, D. A., Heaney, N. B. & Holyoake, T. L. Optimising chronic myeloid leukaemia therapy in the face of resistance to tyrosine kinase inhibitors\a synthesis of clinical and laboratory data. Blood Rev. 24, 1-9 (2010).
34. Nicholson, E. & Holyoake, T. The chronic myeloid leukemia stem cell. Clin. Lymphoma Myeloma 9 (Suppl. 4), 376-381 (2009).
35. Sawyers, C. L. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin. Haematol. 10, 223-231 (1997).
36. Brehme, M. et al. Charting the molecular network of the drug target Bcr\Abl. Proc. Natl Acad. Sci. USA 106, 7414-7419 (2009).
37. Brennan, D. J., O'Connor, D. P., Rexhepaj, E., Ponten, F. & Gallagher, W. M. Antibody-based proteomics: towards the implementation of personalised diagnostic and predictive protocols for cancer patients. Nature Rev. Cancer 10, 605-617 (2010).
38. Dhillon, A. S., von Kriegsheim, A., Grindlay, J. & Kolch, W. Phosphatase and feedback regulation of Raf-1 signaling. Cell Cycle 6, 3-7 (2007).
39. Nguyen, A. et al. Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo. Mol. Cell Biol. 22, 3035-3045 (2002).
40. Kortum, R. L. & Lewis, R. E. The molecular scaffold KSR1 regulates the proliferative and oncogenic potential of cells. Mol. Cell Biol. 24, 4407-4416 (2004).
41. Lozano, J. et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic Ras signaling in mice. Cancer Res. 63, 4232-4238 (2003).
42. McKay, M. M., Ritt, D. A. & Morrison, D. K. Signaling dynamics of the KSR1 scaffold complex. Proc. Natl Acad. Sci. USA 106, 11022-11027 (2009).
43. Rajakulendran, T., Sahmi, M., Lefrancois, M., Sicheri, F. & Therrien, M. A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461, 542-545 (2009).
44. Casar, B., Pinto, A. & Crespo, P. Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol. Cell 31, 708-721 (2008).
45. Liu, L. et al. Proteomic characterization of the dynamic KSR-2 interactome, a signaling scaffold complex in MAPK pathway. Biochim.Biophys. Acta 1794, 1485-1495 (2009).
46. Rauch, J. et al. Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription. Cancer Res. 70, 1679-1688 (2010).
47. Levchenko, A., Bruck, J. & Sternberg, P. W. Scaffold proteins may biphasically affect the levels of mitogen-activated protein kinase signaling and reduce its threshold properties. Proc. Natl Acad. Sci. USA 97, 5818-5823 (2000).
48. Dougherty, M. K. et al. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol. Cell 34, 652-662 (2009).
49. Costanzo-Garvey, D. L. et al. KSR2 is an essential regulator of AMP kinase, energy expenditure, and insulin sensitivity. Cell Metab. 10, 366-378 (2009).
50. Mazurek, S., Drexler, H. C., Troppmair, J., Eigenbrodt, E. & Rapp, U. R. Regulation of pyruvate kinase type M2 by A-Raf: a possible glycolytic stop or go mechanism. Anticancer Res. 27, 3963-3971 (2007).
51. Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
52. Macek, B., Mann, M. & Olsen, J. V. Global and site-specific quantitative phosphoproteomics: principles and applications. Annu. Rev. Pharmacol. Toxicol. 49, 199-221 (2009).
53. Oppermann, F. S. et al. Large-scale proteomics analysis of the human kinome. Mol. Cell Proteomics 8, 1751-1764 (2009).
54. Mayya, V. & Han, D. K. Phosphoproteomics by mass spectrometry: insights, implications, applications and limitations. Expert Rev. Proteomics 6, 605-618 (2009).
55. Olsen, J. V. et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 127, 635-648 (2006).
56. Schmezle, K. & White, F. M. Phosphoproteomic approaches to elucidate cellular signaling networks. Curr. Opin. Biotechnol. 17, 406-414 (2006).
57. Blagoev, B., Ong, S. E., Kratchmarova, I. & Mann, M. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nature Biotechnol. 22, 1139-1145 (2004).
58. Kratchmarova, I., Blagoev, B., Haack-Sorensen, M., Kassem, M. & Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 308, 1472-1477 (2005).
59. Ball, S. G., Shuttleworth, C. A. & Kielty, C. M. Platelet-derived growth factor receptors regulate mesenchymal stem cell fate: implications for neovascularization. Expert Opin. Biol. Ther. 10, 57-71 (2010).
60. Heibeck, T. H. et al. An extensive survey of tyrosine phosphorylation revealing new sites in human mammary epithelial cells. J. Proteome Res. 8, 3852-3861 (2009).
61. Gan, H. K., Kaye, A. H. & Luwor, R. B. The EGFRvIII variant in glioblastoma multiforme. J. Clin. Neurosci. 16, 748-754 (2009).
62. Huang, P. H. et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl Acad. Sci. USA 104, 12867-12872 (2007).
63. Guo, A. et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc. Natl Acad. Sci. USA 105, 692-697 (2008).
64. Amit, I. et al. A module of negative feedback regulators defines growth factor signaling. Nature Genet. 39, 503-512 (2007).
65. Govindan, R. A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer. Clin. Lung Cancer 11, 8-12 (2010).
66. Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-1203 (2007).
67. Wolf-Yadlin, A. et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol. Syst. Biol. 2, 54 (2006).
68. Kumar, N., Wolf-Yadlin, A., White, F. M. & Lauffenburger, D. A. Modeling HER2 effects on cell behavior from mass spectrometry phosphotyrosine data. PLoS Comput. Biol. 3, e4 (2007).
69. Villen, J. & Gygi, S. P. The SCX/IMAC enrichment approach for global phosphorylation analysis by mass spectrometry. Nature Protoc. 3, 1630-1638 (2008).
70. Bodenmiller, B., Mueller, L. N., Mueller, M., Domon, B. & Aebersold, R. Reproducible isolation of distinct, overlapping segments of the phosphoproteome. Nature Methods 4, 231-237 (2007).
71. Choudhary, C. et al. Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol. Cell 36, 326-339 (2009).
72. Chen, Y. et al. Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res. 69, 3713-3720 (2009).
73. Siu, M. K. et al. Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion. Int. J. Cancer 127, 21-31 (2010).
74. Tiedemann, R. E. et al. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 11 5, 1594-1604 (2010).
75. Bonte, D. et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia 10, 920-931 (2008).
76. Hall, M. C. Proteomics modifies our understanding of cell cycle complexity. Sci. Signal. 3, pe4 (2010).
77. Shimoji, S., Park, K. & Hart, G. W. Dynamic crosstalk between GlcNacylation and phosphorylation: roles in signaling, transcription and human disease. Curr. Signal Transduction Therapy 5 (Supp.), 25-40 (2010).
78. Hart, G. W., Housley, M. P. & Slawson, C. Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446, 1017-1022 (2007).
79. Wang, Z. et al. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates cytokinesis. Sci. Signal. 3, ra2 (2010).
80. Chalkley, R. J., Thalhammer, A., Schoepfer, R. & Burlingame, A. L. Identification of protein O-GlcNAcylation sites using electron transfer dissociation mass spectrometry on native peptides. Proc. Natl Acad. Sci. USA 106, 8894-8899 (2009).
81. Wu, S. L. et al. Dynamic profiling of the post-translational modifications and interaction partners of epidermal growth factor receptor signaling after stimulation by epidermal growth factor using Extended Range Proteomic Analysis (ERPA). Mol. Cell Proteomics 5, 1610-1627 (2006).
82. Yang, W. L., Wu, C. Y., Wu, J. & Lin, H. K. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 9, 486-497 (2010).
83. Kitagawa, K., Kotake, Y. & Kitagawa, M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci. 100, 1374-1381 (2009).
84. Ardley, H. C. Ring finger ubiquitin protein ligases and their implication to the pathogenesis of human diseases. Curr. Pharm. Des. 15, 3697-3715 (2009).
85. Vlachostergios, P. J., Patrikidou, A., Daliani, D. D. & Papandreou, C. N. The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation. J. Cell. Mol. Med. 13, 3006-3018 (2009).
86. Vlachostergios, P. J., Patrikidou, A., Daliani, D. D. & Papandreou, C. N. The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation. J. Cell. Mol. Med. 13, 3019-3031 (2009).
87. Nakayama, K. I. & Nakayama, K. Ubiquitin ligases: cell-cycle control and cancer. Nature Rev. Cancer 6, 369-381 (2006).
88. Mani, A. & Gelmann, E. P. The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. 23, 4776-4789 (2005).
89. Coutts, A. S., Adams, C. J. & La Thangue, N. B. p53 ubiquitination by Mdm2: a never ending tail? DNA Repair 8, 483-490 (2009).
90. Marine, J. C. & Lozano, G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Diff. 17, 93-102 (2010).
91. Yang, Y. L., Kitagaki, J., Wang, H., Hou, D. X. & Perantoni, A. O. Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci. 100, 24-28 (2009).
92. Hoeller, D. & Dikic, I. Targeting the ubiquitin system in cancer therapy. Nature 458, 438-444 (2009).
93. Ande, S. R., Chen, J. J. & Maddika, S. The ubiquitin pathway: an emerging drug target in cancer therapy. Eur. J. Pharm. 625, 199-205 (2009).
94. Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nature Rev. Drug Discov. 5, 596-613 (2006).
95. Tang, X. et al. Genome-wide surveys for phosphorylation-dependent substrates of SCF ubiquitin ligases. Methods Enzymol. 399, 433-458 (2005).
96. Bai, C. et al. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-Box. Cell 86, 263-274 (1996).
97. Radivojac, P. et al. Identification, analysis, and prediction of protein ubiquitination sites. Proteins 78, 365-380 (2010).
98. Irish, J. M. et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 11 8, 217-228 (2004).
99. Angers, S. et al. Molecular architecture and assembly of the DDB1-CUL4A ubiquitin ligase machinery. Nature 443, 590-593 (2006).
100. Jeram, S. M. et al. An improved SUMmOn-based methodology for the identification of ubiquitin and ubiquitin-like protein conjugation sites identifies novel ubiquitin-like protein chain linkages. Proteomics 10, 254-265 (2010).
101. Burande, C. F. et al. A label-free quantitative proteomics strategy to identify E3 ubiquitin ligase substrates targeted to proteasome degradation. Mol. Cell. Proteomics 8, 1719-1727 (2009).
102. Merbl, Y. & Kirschner, M. W. Large-scale detection of ubiquitination substrates using cell extracts and protein microarrays. Proc. Natl Acad. Sci. USA 106, 2543-2548 (2009).
103. Persaud, A. et al. Comparison of substrate specificity of the ubiquitin ligases Nedd4 and Nedd4-2 using proteome arrays. Mol. Syst. Biol. 5, 333 (2009).
104. Chen, C. & Matesic, L. E. The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer Metastasis Rev. 26, 587-604 (2007).
105. Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511-1516 (2008).
106. Irish, J. M., Kotecha, N. & Nolan, G. P. Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nature Rev. Cancer 6, 146-155 (2006).
107. Kreeger, P. K. & Lauffenburger, D. A. Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8 (2010).
108. Taylor, I. W. et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nature Biotechnol. 27, 199-204 (2009).
109. Tan, C. S. et al. Comparative analysis reveals conserved protein phosphorylation networks implicated in multiple diseases. Sci. Signal. 2, ra39 (2009).
110. Fenselau, C. A review of quantitative methods for proteomic studies. J. Chromatogr. B 855, 14-20 (2007).
111. Van den Bergh, G. & Arckens, L. Recent advances in 2D electrophoresis: an array of possibilities. Expert Rev. Proteomics 2, 243-252 (2005).
112. Pan, S. & Aebersold, R. Quantitative proteomics by stable isotope labeling and mass spectrometry. Methods Mol. Biol. 367, 209-218 (2007).
113. Wepf, A., Glatter, T., Schmidt, A., Aebersold, R. & Gstaiger, M. Quantitative interaction proteomics using mass spectrometry. Nature Methods 6, 203-205 (2009).
114. Linscheid, M. W., Ahrends, R., Pieper, S. & Kuhn, A. Liquid chromatography-mass spectrometry-based quantitative proteomics. Methods Mol. Biol. 564, 189-205 (2009).
115. Bantscheff, M., Schirle, M., Sweetman, G., Rick, J. & Kuster, B. Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem. 389, 1017-1031 (2007).
116. Everley, P. A., Krijgsveld, J., Zetter, B. R. & Gygi, S. P. Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol. Cell. Proteomics 3, 729-735 (2004).
117. Mann, M. Functional and quantitative proteomics using SILAC. Nature Rev. Mol. Cell Biol. 7, 952-958 (2006).
118. Ong, S. E. et al. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386 (2002).
119. Beynon, R. J. & Pratt, J. M. Metabolic labeling of proteins for proteomics. Mol. Cell. Proteomics 4, 857-872 (2005).
120. Kruger, M. et al. SILAC mouse for quantitative proteomics uncovers kindlin-3 as an essential factor for red blood cell function. Cell 134, 353-364 (2008).
121. Gygi, S. P. et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nature Biotech. 17, 994-999 (1999).
122. Ross, P. L. et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154-1169 (2004).
123. Gerber, S. A., Rush, J., Stemman, O., Kirschner, M. W. & Gygi, S. P. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl Acad. Sci. USA 100, 6940-6945 (2003).
124. Haqqani, A. S., Kelly, J. F. & Stanimirovic, D. B. Quantitative protein profiling by mass spectrometry using label-free proteomics. Methods Mol. Biol. 439, 241-256 (2008).
125. Negishi, A. et al. Large-scale quantitative clinical proteomics by label-free liquid chromatography and mass spectrometry. Cancer Sci. 100, 514-519 (2009).
126. Kopf, E. & Zharhary, D. Antibody arrays\an emerging tool in cancer proteomics. Int. J. Biochem. Cell Biol. 39, 1305-1317 (2010).
127. Haab, B., Dunham, M. & Brown, P. Protein microarrays for highly parallel detection and quantitation of specific proteins and antibodies in complex solutions. Genome Biol. 2, research0004 (2001).
128. Rino, J., Braga, J., Henriques, R. & Carmo-Fonseca, M. Frontiers in fluorescence microscopy. Int. J. Dev. Biol. 53, 1569-1579 (2009).
129. Goldstein, D. M., Gray, N. S. & Zarrinkar, P. P. High-throughput kinase profiling as a platform for drug discovery. Nature Rev. Drug Discov. 7, 391-397 (2008).
130. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
131. Fedorov, O., Muller, S. & Knapp, S. The (un)targeted cancer kinome. Nature Chem. Biol. 6, 166-169 (2010).
132. Kubota, K. et al. Sensitive multiplexed analysis of kinase activities and activity-based kinase identification. Nature Biotechnol. 27, 933-940 (2009).
133. Khan, I. H. et al. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay Drug Dev. Technol. 8, 27-36 (2010).
134. Wu, D., Sylvester, J. E., Parker, L. L., Zhou, G. & Kron, S. J. Peptide reporters of kinase activity in whole cell lysates. Biopolymers 94, 475-486 (2010).
135. Parikh, K., Peppelenbosch, M. P. & Ritsema, T. Kinome profiling using peptide arrays in eukaryotic cells. Methods Mol. Biol. 527, 269-280 (2009).
136. Rix, U. & Superti-Furga, G. Target profiling of small molecules by chemical proteomics. Nature Chem. Biol. 5, 616-624 (2009).
137. Chi, P., Allis, C. D. & Wang, G. G. Covalent histone modifications\miswritten, misinterpreted and mis-erased in human cancers. Nature Rev. Cancer 10, 457-469 (2010).
138. Young, N. L. et al. High throughput characterization of combinatorial histone codes. Mol. Cell. Proteomics 8, 2266-2284 (2009).
139. Zhou, Q. et al. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 10, 1029-1039 (2010).
140. Deribe, Y. L. et al. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci. Signal. 2, ra84 (2009).
141. Rocks, O., Peyker, A. & Bastiaens, P. I. Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors. Curr. Opin. Cell Biol. 18, 351-357 (2006).
142. Hao, D. & Rowinsky, E. K. Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors. Cancer Invest. 20, 387-404 (2002).
143. Yang, W., Di Vizio, D., Kirchner, M., Steen, H. & Freeman, M. R. Proteome scale characterization of human S-acylated proteins in lipid raft-enriched and non-raft membranes. Mol. Cell. Proteomics 9, 54-70 (2010).
144. Spickett, C. M., Pitt, A. R., Morrice, N. & Kolch, W. Proteomic analysis of phosphorylation, oxidation and nitrosylation in signal transduction. Biochim. Biophys. Acta 1764, 1823-1841 (2006).
145. Wilson, K. J., Gilmore, J. L., Foley, J., Lemmon, M. A. & Riese, D. J. 2nd. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol. Ther. 122, 1-8 (2009).
146. Citri, A. & Yarden, Y. EGF-ERBB signalling: towards the systems level. Nature Rev. Mol. Cell Biol. 7, 505-516 (2006).
147. Yao, Z. & Seger, R. The ERK signaling cascade\views from different subcellular compartments. Biofactors 35, 407-416 (2009).
148. McKay, M. M. & Morrison, D. K. Integrating signals from RTKs to ERK/MAPK. Oncogene 26, 3113-3121 (2007).
149. Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290 (2007).
150. Preisinger, C. & Kolch, W. The Bcr-Abl kinase regulates the actin cytoskeleton via a GADS/Slp-76/Nck1 adaptor protein pathway. Cell Signal. 22, 848-856 (2010).
151. Dyson, J. M. et al. The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin. J. Cell Biol. 155, 1065-1079 (2001).
152. Ikeda, F. & Dikic, I. Atypical ubiquitin chains: new molecular signals. EMBO Rep. 9, 536-542 (2008).
153. Schwartz, A. L. & Ciechanover, A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu. Rev. Pharmacol. Toxicol. 49, 73-96 (2009).